BioAtla (BCAB) Q2 Loss Narrows 27%
BioAtla (NASDAQ:BCAB), a clinical-stage biotech developing therapies for hard-to-treat cancers, released its second quarter 2025 results on August 7, 2025. The company posted a net loss per share of $(0.32) (GAAP), improved from a $(0.44) GAAP net loss per share in Q2 2024. Revenue (GAAP) was $0.0 million, as expected for a company with no approved products. Research and development (R&D) and general and administrative (G&A) expenses (GAAP) both dropped year over year, helping narrow the operating loss. Despite progress on several clinical programs and tighter cost controls, there was a major decline in cash reserves, with cash and cash equivalents (GAAP) decreasing from $49.0 million as of December 31, 2024 to $18.2 million as of June 30, 2025, highlighting risks around future funding and ongoing operations.
Source: Analyst estimates for the quarter provided by FactSet.
BioAtla develops precision antibody therapies to treat solid tumors. Its central technology, known as Conditionally Active Biologic (CAB), designs antibodies that become active in the acidic environments typical of cancer cells but remain inactive in healthy tissues. This approach aims to reduce treatment side effects and deliver more effective therapies.
Source Fool.com
